Stock Analysis

Qliro Full Year 2024 Earnings: kr1.42 loss per share (vs kr0.21 profit in FY 2023)

OM:QLIRO
Source: Shutterstock

Qliro (STO:QLIRO) Full Year 2024 Results

Key Financial Results

  • Revenue: kr291.4m (down 11% from FY 2023).
  • Net loss: kr27.5m (down from kr4.10m profit in FY 2023).
  • kr1.42 loss per share (down from kr0.21 profit in FY 2023).
earnings-and-revenue-growth
OM:QLIRO Earnings and Revenue Growth February 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Qliro Earnings Insights

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 9.2% growth forecast for the Consumer Finance industry in Europe.

Performance of the market in Sweden.

The company's shares are down 2.7% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Qliro that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if Qliro might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:QLIRO

Qliro

Operates as a fintech company.

High growth potential with adequate balance sheet.

Similar Companies

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor